Company Interview / Maintaining dividends in a tough market

Jason Beddow MD of Argo Investments recaps FY24 in which the LIC posted a full year profit of $253 million, a decrease of 6.8% from the previous year. The company associates the fall with lower dividends from its overall investments, among which Rio Tinto (ASX: RIO), BHP (ASX: BHP) and Woodside (ASX: WDS) were identified.

From a more company-centric perspective, Jason addresses the impact of varying industries on Argo's operations. He notes, for instance, that the health care sector has been particularly challenging. That being said, Argo’s investment in Clarity Pharmaceuticals (ASX: CU6) although initially risky, has proven rewarding. Evolving patient behaviours and the struggle with higher costs, however, have posed challenges for traditional healthcare stocks such as Ramsay Healthcare (ASX: RCH) and Sonic Health (ASX: SHL).

Despite the decrease in profitability, the company has managed to maintain its dividend at $0.18 per share with the possibility of a special payment. Jason further mentions some obstacles posed by recent trends, namely the exits of companies from the ASX 200 and the unfulfilled potential of big IPOs.

Assessing the situation, Jason concludes the dialogue by emphasising Argo's upcoming focus on reevaluating and adjusting strategies as a necessary response to the shifting market conditions.